Jianyuan Pharmaceutical and Peptide Biotechnology have reached a strategic partnership

On July 30, Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. and Shenzhen Peptide Sheng Biotechnology Co., Ltd. signed an agreement and reached a strategic cooperation relationship. The two parties will integrate resources, jointly explore the market, promote business innovation of both parties, and further promote the development of medical beauty products, the discovery and development of innovative peptide drugs. Dr. Wang Zhuyin, founder and chairman of Shenzhen Peptide Sheng Biotechnology Co., Ltd., and Wang Yirong, BD director of Peptide Sheng; Yao Zhiyong, general manager of Jianyuan Pharmaceutical Technology Co., Ltd., Li Xinyu, deputy general manager, Dr. Zhang Lixiang, director of the project management center, and Fu Yuqing, director of research and development, attended the signing ceremony.

Shenzhen Peptide Sheng Biotechnology Co., Ltd.

Shenzhen Peptide Sheng Biotechnology Co., Ltd. was established in October 2022 and was founded by Dr. Wang Zhuyin. Shenzhen Peptide Sheng is building the world's first entity peptide library that combines peptide structural diversity and sequence diversity, and around the peptide library, it has created a full-process peptide drug discovery technology platform, breaking through the bottleneck of peptide drug discovery and optimization. It can provide global biopharmaceutical companies with active peptide discovery (functional peptides, active peptides, etc.) screening and optimization CRO services to accelerate the development of innovative peptide drugs. Shenzhen Peptide's large-scale innovative peptide library integrates peptide structural diversity and sequence diversity, and incorporates a number of core innovative technologies. It will become the world's unique and most advanced innovative peptide entity library. Based on the peptide drug discovery platform of this high-end peptide library, it provides CRO services to global biopharmaceutical companies in terms of functional active peptides, targeted transmembrane peptides, medical beauty active peptides, targeted delivery peptides and transdermal delivery peptides, and helps the research and development of innovative peptide drugs.

Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.

Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. was established in 2009. It is an innovative pharmaceutical company with independent intellectual property rights that integrates the research and development, production and sales of peptide products. It has two subsidiaries, Shenzhen Jianxiang Biopharmaceutical Co., Ltd. and Hubei Jianxiang Biopharmaceutical Co., Ltd. The main products include peptide API, peptide drug preparations, peptide products in the field of non-human drugs, including health products, cosmetics, veterinary peptides, biomaterials, etc.; CRO&CMO&CDMO&OEM services. Products cover application areas such as medicinal treatment, food, health products, cosmetics, and biomaterials. Most of the products developed are cutting-edge peptide products at home and abroad. The technical level is internationally advanced and domestically leading. It is the preferred partner of global integrated peptide CRO/CMO. In 2018, Jianyuan Pharmaceutical was recognized as the "Guangdong Province Synthetic Peptide Innovative Drug Engineering Technology Center", and won the "Top 20 Chinese CDMO Enterprises in 2021" and "Top Ten Innovation Platforms in Pingshan District in 2022". In 2023, Semaglutide and Liraglutide were recognized as Guangdong Province's famous high-tech products. "A Synthesis Method of Semaglutide" won the 21st Shenzhen Enterprise Innovation Record Product R&D Innovation Project Award and won three 21st Shenzhen Enterprise Innovation Records (China Records).

At present, the scale of China's peptide drug market has reached 67 billion yuan, and it is expected to increase to 112.86 billion yuan in 2025 and 205.65 billion yuan in 2030. It is expected that the global peptide cosmetic raw material market will reach 1.45 billion US dollars by 2025 and 1.97 billion US dollars by 2030, and the scale will continue to expand.

With its leading peptide synthesis technology advantages, outstanding cost control advantages for bulk peptide products, and strict peptide product quality management, Jianyuan Pharmaceutical has formed excellent customization capabilities, possesses core technologies for step-by-step amplification of peptide production, and has a rich production line to meet the needs of different batches of peptide raw materials. The "complex structure peptide library construction technology" created by Peptide Sheng Bio is the world's only most advanced peptide library that integrates peptide structure diversity and sequence diversity. It has discovered and verified in vitro more than 100 targeted transmold peptides, 15+ medical beauty active peptides, 50+ antibacterial peptides, and other active peptides that can be transferred.

Jianyuan Pharmaceutical and Peptide Sheng Bio have joined forces to integrate their respective advantageous resources, deepen empowerment, and jointly promote the development of medical beauty products and innovative peptide drugs, adding new growth to the development of the industry.